|
Volumn 16, Issue 2, 2009, Pages 89-90
|
Targeting the Molecular Defect in BRCA-Deficient Tumors for Cancer Therapy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;
OLAPARIB;
UNCLASSIFIED DRUG;
BREAST CANCER;
CLINICAL TRIAL;
COLORECTAL CANCER;
DOUBLE STRANDED DNA BREAK;
DRUG DOSE ESCALATION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TARGETING;
DRUG TOLERABILITY;
GENE MUTATION;
GENETIC PREDISPOSITION;
GENETIC RISK;
HETEROZYGOTE;
HOMOLOGOUS RECOMBINATION;
HUMAN;
MELANOMA;
ONCOGENE;
OVARY CANCER;
PRIORITY JOURNAL;
PROSTATE CANCER;
SHORT SURVEY;
|
EID: 67651180861
PISSN: 15356108
EISSN: None
Source Type: Journal
DOI: 10.1016/j.ccr.2009.07.011 Document Type: Short Survey |
Times cited : (12)
|
References (9)
|